Nomination Committee’s proposal for election of Board members 2024

The Nomination Committee of Boule Diagnostics AB has decided to propose to the Annual General Meeting 2024 (AGM) that the number of Board members shall be six, including the Chair. The Nomination Committee proposes re-election of Karin Dahllöf, Thomas Eklund, Emil Hjalmarsson, Torben Jørgensen and Yvonne Mårtensson, and that Torben Jørgensen is re-elected as the Chairman of the Board. Furthermore, Rikke Rytter is proposed as a new Board member.

Rikke Rytter has extensive sales and marketing expertise from the Life Sciences and Diagnostic sectors, with a career spanning from 1995. She has worked in various commercial roles for major global companies such as Cytiva (formerly Pharmacia Biotech, GE Healthcare), Biotage, Dako, Sysmex and currently Genovis where she has supported and cultivated international teams to develop successful products tailored to meet customer needs.

Detailed information about the proposed board members can be found on Boule’s website.

The Nomination Committee’s complete proposal for a decision before the 2024 AGM as well as their reasoned statement will be submitted at the latest in connection with the publication of the notice to the AGM.

For more information, please contact:
Erik Ivarsson, Chairman of the Nomination Committee, erik.ivarsson@grenspecialisten.com, phone +46 (0)73-389 07 52

Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Holger Lembrér, CFO, Boule Diagnostics AB, phone. +46 (0)72-230 77 10

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

This information was submitted for publication, through the agency of the contact person set out above, at 12:15 CET on March 4, 2024.

Nomination Committee’s proposal for election of Board members 2024 of Boule Diagnostics